A carregar...
Investigational Immunotherapeutics for B-Cell Malignancies
The use of rituximab-based chemoimmunotherapy regimens has remarkably improved the response rates, long-term outcomes, and quality of life of patients with B-cell malignancies. However, a substantial number of patients exhibit either primary or acquired resistance to rituximab, which suggests that n...
Na minha lista:
| Publicado no: | J Clin Oncol |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Society of Clinical Oncology
2010
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4872311/ https://ncbi.nlm.nih.gov/pubmed/20048186 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2009.22.8254 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|